Broncholab

by Fluidda (Broncholab)  · Based in Belgium → — Respiratory healthcare Optimized by engineering and artificial intelligence
Pulmonology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

Broncholab, developed by Fluidda, is an AI-powered diagnostic platform that utilizes Functional Respiratory Imaging (FRI) technology to provide detailed, regional lung function insights. It analyzes high-resolution CT scan data to deliver quantitative parameters for pulmonary tissue, assisting physicians in the diagnosis, documentation, and monitoring of various respiratory conditions.

The platform converts CT scan images into three-dimensional reconstructions of anatomical structures, such as airways and lung volumes, and employs accurate computer simulations, including Computational Fluid Dynamics (CFD), to add a unique level of functionality to the scan output. This technology provides reproducible CT values for pulmonary tissue, offering quantitative support for diagnosis and follow-up examinations.

Broncholab’s capabilities extend to 3D segmentation and isolation of sub-compartments, volumetric analysis, density evaluations, low-density cluster analysis, fissure evaluation, and comprehensive reporting tools, all integrated into a dedicated workflow. It aims to provide more accurate and clinically relevant information than conventional lung function tests, enabling early and correct diagnosis and optimizing treatments for individual patients.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Functional Respiratory Imaging (FRI)
  • Quantitative HRCT analysis
  • Regional lung function visualization
  • Disease progression monitoring
  • Therapy optimization support
  • 3D segmentation and isolation of sub-compartments
  • Volumetric analysis
  • Density evaluations
  • Low density cluster analysis
  • Fissure evaluation
  • Reporting tools
  • Computational Fluid Dynamics (CFD)
  • AI/Machine Learning algorithms

Use Cases

  • Diagnosing respiratory diseases
  • Monitoring respiratory diseases
  • Optimizing treatment for individual patients
  • Early and correct diagnosis of lung conditions
  • Supporting clinical trials for new respiratory drugs
  • Assessing patient's lung function and disease progression
  • Detecting changes in lung structure (e.g., pulmonary vascular remodeling)
  • Personalized medicine for respiratory care

What Physicians Need to Know

DICOM Support & Standards
Broncholab is a Software as Medical Device (SaMD) that provides quantitative CT values to support diagnosis and documentation of pulmonary tissue images from CT scans. DICOM is the global standard for managing medical images, and DICOM modality codes (e.g., CT, MR, US) identify the type of equipment or method that created a series of images.
PACS Integration Method
Broncholab generates reports that are saved directly onto a hospital's Picture Archiving and Communication System (PACS).
Reading Room Workflow Impact
Broncholab provides physicians with reproducible CT values for pulmonary tissue, offering quantitative support for diagnosis and follow-up examinations. It enables accurate monitoring of lung diseases, increasing insights into the disease's nature and supporting physicians in diagnosis and follow-up. The platform offers 3D segmentation and isolation of subcompartments, volumetric analysis, density evaluations, low-density cluster analysis, fissure evaluation, and reporting tools, all combined within a dedicated workflow.
AI Model Architecture (deep learning approach)
Broncholab utilizes Artificial Intelligence technology, combining it with high-resolution CT scans and computational fluid dynamics. The platform leverages AI, cloud, and deep learning to convert 2D images into 3D reconstructions of anatomical structures. This allows for precise recognition of small details in pulmonary tissue images. Functional Respiratory Imaging (FRI), which is central to Broncholab, combines HRCT scans, computational fluid dynamics, and AI.
Processing Speed (per study)
Not specified.
FDA Clearance Pathway (510k/De Novo)
Broncholab received FDA 510(k) clearance in March 2020.
Supported Modalities (CT/MRI/X-ray/US)
Broncholab analyzes images obtained from CT thoracic datasets. It specifically uses high-resolution CT (HRCT) scans.
RSNA/ACR Validation
Fluidda introduced Broncholab to radiologists at the RSNA (Radiological Society of North America) congress in 2021. The congress highlighted the growing importance of quantitative imaging modalities, such as Broncholab.
Physician Tip

Broncholab provides detailed quantitative representations of CT images, offering reproducible CT values for pulmonary tissue. This can significantly enhance the diagnosis and follow-up of respiratory diseases by providing insights into the nature of the disease and enabling early adjustments to therapy. The platform's 3D segmentation, volumetric analysis, and density evaluations offer a comprehensive view beyond conventional lung function tests. Consider using Broncholab for personalized medicine approaches, as it helps optimize diagnosis, monitor disease progression, and assess the effects of therapy.

Broncholab is designed to integrate into existing radiology workflows by saving generated reports directly onto a hospital's PACS. The platform is accessible via an online portal, allowing for the upload and analysis of CT-scan data.

Details

Category Radiology & Imaging AI
Pricing Unknown
Compliance
BAA AvailableUnknown
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Pulmonology, Radiology

What the Web Says

Broncholab, developed by Fluidda, is a diagnostic platform that utilizes Functional Respiratory Imaging (FRI) to provide detailed, regional lung function insights, aiding in the diagnosis and monitoring of respiratory diseases. It analyzes CT scan data using FRI technology to deliver quantitative parameters for pulmonary tissue, supporting physicians in diagnosing and monitoring respiratory conditions. The platform has received FDA clearance in March 2020 and CE certification in June 2022, ensuring its clinical applicability in the U.S. and Europe.

Overall: Positive

Strengths

  • Provides detailed, regional lung function insights, which can lead to more accurate diagnoses and personalized treatment plans.
  • Offers quantitative HRCT analysis, including 3D segmentation, volumetric analysis, and density evaluations.
  • Aids in monitoring disease progression and optimizing therapy for individual patients.
  • Utilizes Functional Respiratory Imaging (FRI), combining high-resolution CT scans, computational fluid dynamics, and artificial intelligence.
  • Can identify changes in lung structure associated with various pulmonary diseases.
  • Helps overcome the limitations of conventional lung function tests like spirometry, which can underestimate disease severity.

Limitations

No significant limitations found in public reviews. Consider checking vendor documentation or requesting a demo for a thorough evaluation.

Based on reviews from: healthaidb.com, nih.gov, fluidda.com, broncholab.com, fiercebiotech.com, auntminnie.com, prnewswire.com, healthcaretechoutlook.com, massdevice.com

Last updated: 2026-10-30

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Broncholab

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
FDA Clears Fluidda's Broncholab Platform for Use in Clinical Practice
The US Food and Drug Administration provided market clearance to Fluidda for its Broncholab platform in March 2020. Broncholab offers Functional Respiratory Imaging (FRI) parameters to physicians via an online platform to assist in diagnosing and monitoring respiratory diseases.
2020-03
MassDevice
FDA clears Fluidda's high-res respiratory imaging software
Fluidda announced that the FDA cleared its Broncholab software in March 2020, designed to assist in diagnosing and monitoring respiratory diseases for clinical use. The Broncholab platform provides functional respiratory imaging (FRI) parameters to physicians through an online platform.
2020-03
AuntMinnie.com
FDA clears Fluidda respiratory imaging platform
The U.S. Food and Drug Administration (FDA) cleared Fluidda's functional respiratory imaging (FRI) online platform, Broncholab, in March 2020. This platform provides FRI parameters to physicians to aid in the diagnosis and monitoring of respiratory diseases and to advance personalized medicine.
2020-03
FierceBiotech
Fluidda's Broncholab software cleared by FDA for lung function analysis
In March 2020, the FDA cleared Fluidda's Broncholab software, a digital imaging platform that provides doctors with insights into lung function to diagnose respiratory diseases. The software derives biomarkers from low-dose CT scans, including maps of ventilation, trapped air pockets, and airway and nodule volume.
2020-03
Fluidda
Broncholab™ Offers Respiratory Solutions Optimize Treatment of Lung Patients – USA & EU
Broncholab™, developed by Fluidda, offers respiratory solutions to optimize the treatment of individual lung patients by analyzing CT-scan data using FRI-technology. The results are sent to the attending physician, adhering to privacy requirements.
2022-07
Fluidda
Broncholab® Platform Obtains CE Certificate
In June 2022, Fluidda obtained a CE Certificate for its Broncholab platform, allowing its use by physicians in the European Union, Iceland, Liechtenstein, and Norway. The platform provides Functional Respiratory Imaging (FRI) parameters to assist in diagnosing and monitoring respiratory diseases.
2022-06
Fluidda
RSNA 2021 – Imaging quantification like Broncholab trending topic at RSNA conference
Fluidda introduced its new medical device, Broncholab, to radiologists for the first time at the RSNA 2021 congress. Broncholab is a diagnostic support tool that uses FRI technology to detect and improve therapy for lung diseases, enabling accurate monitoring and supporting physicians in diagnosis and follow-up.
2021-12
NIH.gov
Quantitative Computed Tomography in Chronic Obstructive Pulmonary Disease: A Review of Commercial Platforms
This peer-reviewed article from April 2022 reviews commercial platforms for quantitative computed tomography (QCT) in COPD, highlighting FLUIDDA's Broncholab platform. Broncholab utilizes functional respiratory imaging (FRI) with high-resolution CT (HRCT) to create 3D airway models for computational fluid dynamics simulations and provides QCT-based metrics like lobe volumes and emphysema scores.
2022-04

Videos

Product demos, reviews, and walkthroughs for Broncholab.

Loading videos...

View all on YouTube

Frequently Asked Questions

Broncholab uses AI in conjunction with Functional Respiratory Imaging (FRI), which combines high-resolution CT scans and computational fluid dynamics, to provide quantitative data for pulmonary tissue. It addresses concerns by offering detailed 3D segmentation, volumetric analysis, density evaluations, and low-density cluster analysis, which can aid in diagnosing and monitoring respiratory diseases with more accurate regional information than conventional tests.
Broncholab has received FDA clearance in the United States (March 2020) and CE certification in June 2022. This allows its use by physicians in the European Union, Iceland, Liechtenstein, and Norway, in addition to the US.
While Broncholab offers unique Functional Respiratory Imaging (FRI) parameters, other quantitative CT (QCT) software platforms also provide similar information for assessing lung conditions. For example, VIDA's QCT software Apollo offers airway remodeling analysis with its segmentation tool, and both Fluidda and VIDA explore vessel segmentation. AI-powered tools for lung cancer screening and nodule detection are also available, such as Optellum's Virtual Nodule Clinic.
Broncholab operates on a subscription-based pricing model. Specific pricing details are not publicly available and require contacting the vendor directly.
While beneficial, AI in radiology, including platforms like Broncholab, has limitations. AI models can sometimes produce 'hallucinations' or unsupported statements in reports, and their effect on radiologist performance can be inconsistent, improving some while worsening others. Additionally, current AI systems are predominantly image-based and may not inherently incorporate procedural or clinical information, which can lead to misinterpretations if not integrated with clinical context.

Compare Broncholab

VS
SwiftMR vs Broncholab
Radiology & Imaging AI Adjacent · 65/100
SwiftMR focuses on enhancing the efficiency and image quality of MRI scans across all body parts and sequences, making it suitable for general radiology departments seeking operational improvements.…
VS
QuickRad vs Broncholab
Radiology & Imaging AI Adjacent · 65/100
QuickRad is a comprehensive AI-integrated PACS/RIS system designed to optimize general radiology workflows and reporting efficiency. In contrast, Broncholab is a specialized AI-powered diagnostic platform focused on providing…
VS
D2P vs Broncholab
Radiology & Imaging AI Adjacent · 65/100
Tool A (D2P) is designed for creating patient-specific 3D anatomical models from various imaging modalities for surgical planning and 3D printing. In contrast, Tool B (Broncholab) specializes in…

Related Tools

a2z Radiology AI Inc.
a2z Radiology AI Inc.
Clinical Decision Support & Reference
Abdo-Triage is an AI tool by a2z Radiology AI Inc. designed to assist radiologists in triaging abdominal imaging studies and identifying critical findings.
Perimeter Medical Imaging AI
Perimeter Medical Imaging AI
Clinical Decision Support & Reference
The Claire OCT System by Perimeter Medical Imaging AI uses Optical Coherence Tomography and AI to provide real-time, high-resolution tissue imaging during surgery to help identify cancerous tissue.
SOPHiA DDM
SOPHiA GENETICS
Oncology AI
SOPHiA DDM™ is an AI-driven and cloud-powered platform that helps clinicians generate real-time, actionable insights for patients with cancer and rare disorders by analyzing complex genomic, radiomic, and multimodal data.
Paid
Qure.ai QXR
Qure.ai
Clinical Decision Support & Reference
Qure.ai QXR is an AI-powered solution for chest X-ray interpretation, designed to assist radiologists, pulmonologists, and ER physicians in diagnosing various conditions.
DeepBio DeepDx® Prostate
DeepBio
Oncology AI
DeepDx® Prostate leverages deep learning to standardize prostate cancer diagnostics by detecting abnormalities in digital slides with high precision, providing automated Gleason grading, tumor quantification, and tumor length measurements.
CortiCare (Virtual EEG Department)
CortiCare
Neurology AI
CortiCare offers 24/7 remote EEG monitoring and interpretation services, functioning as a virtual EEG department to assist hospitals and neurology practices in identifying seizures and other neurological conditions.

See all Radiology & Imaging AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.